Celcuity Inc.
Case Overview
| Status: | Status: Investigating |
| Company Name: | Company Name: Celcuity Inc. |
| Ticker: | Ticker: CELC |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
On July 14, 2026, Celcuity issued a press release announcing that it had secured U.S. Food and Drug Administration approval for its breast cancer therapy Revtorpyk (gedatolisib) and “anticipates commercial launch in late Q3 2026,” representing a delayed launch timeline relative to analyst expectations. Commenting on the release, Stifel Financial Corp. analyst Stephen Wiley noted that “late 3Q26 launch guidance seems somewhat extended.” Leerink Partners analyst Andrew Berens agreed, noting that while the “approval was largely expected . . . we did not anticipate [a Q3 launch date] given prior commentary on launch readiness.”
On this news, Celcuity’s stock price fell $19.54 per share, or 17.6%, to close at $91.51 per share on July 15, 2026.
On this news, Celcuity’s stock price fell $19.54 per share, or 17.6%, to close at $91.51 per share on July 15, 2026.